KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Depreciation & Amortization (CF) data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 49.76% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $44.5 million, up 18.02%, while the annual FY2025 figure was $44.5 million, 18.02% up from the prior year.
  • Depreciation & Amortization (CF) reached $5.3 million in Q4 2025 per SRPT's latest filing, down from $18.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $18.4 million in Q3 2025 and bottomed at $5.3 million in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $10.3 million, with a median of $10.5 million recorded in 2021.
  • The widest YoY moves for Depreciation & Amortization (CF): up 88.15% in 2025, down 49.76% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $10.1 million in 2021, then increased by 4.02% to $10.6 million in 2022, then grew by 7.76% to $11.4 million in 2023, then fell by 8.06% to $10.5 million in 2024, then crashed by 49.76% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $5.3 million in Q4 2025, $18.4 million in Q3 2025, and $10.8 million in Q2 2025.